References
- Talbott E., Guzick D., Clerici A., Berga S., Detre K., Weimer K., Kuller L. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler. Throm. Vasc. Biol. 1995; 15: 821–6
- Dahlgren E., Janson P. O., Johansson S., Lapidus L., Lindstedt G., Tengbom L. Hemostatic and metabolic variables in women with polycystic ovary syndrome. Fertil. Steril. 1994; 61: 455–60
- Glueck C. J., Glueck H. I., Stroop D., Speirs J., Hamer T., Tracy T. Endogenous testosterone, fibrinolysis, and coronary heart disease risk in hyperlipidemic men. J. Lab. Clin. Med. 1993; 122: 412–20
- Pelzer H., Schwarz A., Stüber W. Determination of human prothrombin activation fragments 1+2 in plasma with an antibody against a synthetic peptide. Thromb. Haemostas. 1991; 65(2)153–9
- Clouse L. H., Comp P. C. The regulation of hemostasis: the protein C system. N. Engl. J. Med. 1986; 314: 1298–1307
- Suzuki K., Nishioka J. Plasma protein S activity measured using Protac, a snake venom derived activator of Protein C. Thromb. Res. 1988; 49: 241–51
- Fearnley G. R., Balmfort G., Fearnley E. Evidence of a diurnal fibrinolytic rhythm with a simple method of measuring natural fibrinolysis. Clin. Sci. 1957; 16: 645–50
- Chmielewska J., Rånby M., Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb. Res. 1983; 31: 427–36
- Soria J., Soria C., Samama M. A plasminogen assay using a chromogenic synthetic substrate: results from clinical work and from studies of thrombolysis. Progress in Chemical Fibrinolysis and Thrombolysis, V. Davidson, et al. Raven Press, New York 1978; vol. 3: 337–46
- Saito H. Afla2 plasmin inhibitor and its deficiency states. J. Lab. Med. 1988; 112: 671–8
- Fless G. M., Snyder M. L., Scanu A. M. Enzyme-linked immunoassay for Lp(a). J. Lip. Res. 1989; 30: 651–62
- Wysowsky D. K., Freiman J. P., Tourtelot J. B., Horton M. L. Fatal and non fatal hepatotoxicity associated with flutamide. Ann. Int. Med. 1993; 118: 860–4